openPR Logo
Press release

Global Radiopharmaceuticals Market Outlook 2020 Report

05-07-2018 08:39 AM CET | Health & Medicine

Press release from: Kuick Resarch

“Global Radiopharmaceuticals Market Outlook 2020” Report Highlight:

* Global Radiopharmaceutical Market Overview
* Global Radiopharmaceuticals Market Dynamics
* FDA & EMA Guidelines for Radiopharmaceuticals
* Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase
* Global Radiopharmaceuticals Clinical Pipeline: 133 Radiopharmaceuticals
* Majority Radiopharmaceuticals in Preclinical Phase: 44 Radiopharmaceuticals
* Marketed Radiopharmaceuticals: 19 Radiopharmaceuticals

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Radiopharmaceuticals-Market-Outlook-2020.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Global Radiopharmaceutical Market Overview

1.1 Current Market Scenario

1.2 Diagnostic & Therapeutic Radiopharmaceuticals

1.3 Global Radiopharmaceticals Clinical Pipeline Overview



2. Global Radiopharmaceuticals Market Dynamics



3. Radioisotopes Used in Radiopharmaceuticals



4. EMA Guidelines for Radiopharmaceuticals

4.1 Physico-Chemical, Biological or Microbiological Tests of Medicinal Products

4.2 Toxicological & Pharmacological Tests

4.3 Clinical Documentation

4.4 Radiation Dosimetry

4.5 Labelling & Packaging



5. FDA Guidelines for Radiopharmaceuticals

5.1 Clinical Indication

5.2 General Considerations for Safety Assessments

5.3 Clinical Evaluation of Medical Imaging Agents



6. Canada Guidelines for Radiopharmaceuticals

6.1 Use of Positron Emitting Radiopharmaceuticals (PERs) in Basic Research

6.2 Use of Positron Emitting Radiopharmaceuticals in Basic Research involving Humans

6.3 Stability Testing of Existing Drug Substances and Products

6.4 Good Manufacturing Practices (GMP) for Positron Emitting Radiopharmaceuticals (PERs)



7. Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase

7.1 Unknown

7.2 Research

7.3 Preclinical

7.4 Phase-0

7.5 Phase-I

7.6 Phase-I/II

7.7 Phase-II

7.8 Phase-II/III

7.9 Phase-III

7.10 Preregistration



8. Marketed Radiopharmaceuticals Clinical Insight by Indication

8.1 Florbetapir F 18 (Amyvid)

8.2 Iobenguane I-123 (AdreView)

8.3 Ibritumomab Tiuxetan (Zevalin & Zevamab)

8.4 Radium-223 Chloride (Alpharadin & Xofigo)

8.5 Tc 99m Tilmanocept (Lymphoseek)

8.6 Florbetaben F18 (NeuraCeq)

8.7 Capromab (ProstaScint)

8.8 Pentetreotide (Oktreotid & 111In)

8.9 Iodine I 131 Derlotuximab Biotin (Cotara)

8.10 Tc 99m Besilesomab (Scintimun)

8.11 Samarium 153 lexidronam (Quadramet)

8.12 Technetium Tc 99m Sulfur Colloid Injection

8.13 Tc 99m Apcitide (AcuTect)

8.14 DW 166HC (Milican)

8.15 Tc 99m Sulesomab (LeukoScan)

8.16 Satumomab (OncoScint CR/OV)

8.17 Pentetreotide (OctreoScan & SomatoTher)

8.18 Tc 99m ior cea1

8.19 Tc 99m Nofetumomab Merpentan (VerLuma)



9. Discontinued & Suspended Radiopharmaceuticals by Indication & Phase

9.1 No Development Reported

9.2 Discontinued

9.3 Market Withdrawal

9.4 Suspended





10. Competitive Landscape

10.1 Avid Radiopharmaceuticals

10.2 Actinium Pharmaceuticals

10.3 AREVA Med

10.4 Bayer HealthCare Pharmaceuticals

10.5 Cardinal Health

10.6 Immunomedics

10.7 Lantheus Medical Imaging

10.8 Merck

10.9 Navidea

10.10 Nordion

10.11 Lantheus Medical Imaging

10.12 GE Healthcare

10.13 Ion Beam Applications

10.14 PETNET Solutions (Siemens Healthcare Global)

Figure 1-1: Global Radiopharmaceuticals Market (US$ Billion), 2014-2020

Figure 1-2: Global Radiopharmaceuticals Market by Region (%), 2014 & 2020

Figure 1-3: Global Radiopharmaceuticals Market by Region (US$ Billion), 2014 - 2020

Figure 1-4: Target Patient Base for Radiopharmaceuticals (Million), 2014-2020

Figure 1-5: Target Patient Base for Radiopharmaceuticals by Region (%), 2014 & 2020

Figure 1-6: Target Patient Base for Radiopharmaceuticals by Region (Million), 2014 - 2020

Figure 1-7: Global Radiopharmceutical Pipeline by Phase (%), 2016

Figure 1-8: Global Radiopharmceutical Pipeline by Phase (Numbers), 2016

Figure 1-9: Suspended & Discontinued Radiopharmceutical Pipeline (%), 2016

Figure 1-10: Suspended & Discontinued Radiopharmceutical Pipeline (Number), 2016

Figure 8-1: Lantheus Medical Imaging Product Pipeline



Table 1-1: Calcium-47 Investigation Properties as Radiopharmaceuticals Drug

Table 1-2: Carbon-11 Investigation Properties as Radiopharmaceuticals Drug

Table 1-3: Carbon-14 Investigation Properties as Radiopharmaceuticals Drug

Table 1-4: Chromium-51 Investigation Properties as Radiopharmaceuticals Drug

Table 1-5: Cobalt-57 Investigation Properties as Radiopharmaceuticals Drug

Table 1-6: Cobalt-58 Investigation Properties as Radiopharmaceuticals Drug

Table 1-7: Erbium-169 Investigation Properties as Radiopharmaceuticals Drug

Table 1-8: Fluorine-18 Investigation Properties as Radiopharmaceuticals Drug

Table 1-9: Gallium-67 Investigation Properties as Radiopharmaceuticals Drug

Table 1-10: Gallium-68 Investigation Properties as Radiopharmaceuticals Drug

Table 1-11: Hydrogen-3 Investigation Properties as Radiopharmaceuticals Drug

Table 1-12: Indium-111 Investigation Properties as Radiopharmaceuticals Drug

Table 1-13: Iodine-123 Investigation Properties as Radiopharmaceuticals Drug

Table 1-14: Iodine-125 Investigation Properties as Radiopharmaceuticals Drug

Table 1-15: Iodine-131 Diagnostic Investigation Properties as Radiopharmaceuticals Drug

Table 1-16: Iodine-131 Therapeutic Investigation Properties as Radiopharmaceuticals Drug

Table 1-17: Iron-59 Investigation Properties as Radiopharmaceuticals Drug

Table 1-18: Krypton-81m Investigation Properties as Radiopharmaceuticals Drug

Table 1-19: Nitrogen-13 Investigation Properties as Radiopharmaceuticals Drug

Table 1-20: Oxygen-15 Investigation Properties as Radiopharmaceuticals Drug

Table 1-21: Phosphorus-32 Investigation Properties as Radiopharmaceuticals Drug

Table 1-22: Radium-223 Investigation Properties as Radiopharmaceuticals Drug

Table 1-23: Rubidium-82 Investigation Properties as Radiopharmaceuticals Drug

Table 1-24: Samarium-153 Investigation Properties as Radiopharmaceuticals Drug

Table 1-25: Selenium-75 Investigation Properties as Radiopharmaceuticals Drug

Table 1-26: Sodium-22 Investigation Properties as Radiopharmaceuticals Drug

Table 1-27: Sodium-24 Investigation Properties as Radiopharmaceuticals Drug

Table 1-28: Strontium-89 Investigation Properties as Radiopharmaceuticals Drug

Table 1-29: Technetium-99m Investigation Properties as Radiopharmaceuticals Drug

Table 1-30: Thallium-201 Investigation Properties as Radiopharmaceuticals Drug

Table 1-31: Xenon-133 Investigation Properties as Radiopharmaceuticals Drug

Table 1-32: Yttrium-90 Investigation Properties as Radiopharmaceuticals Drug

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Radiopharmaceuticals Market Outlook 2020 Report here

News-ID: 1040927 • Views: 331

More Releases from Kuick Resarch

Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research" "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs • Marketed Cancer Antibody Drug Conjugate: 9 Drugs • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 • Majority of Drug Trials Are For Second Line Therapy
Global Cell Therapy Market Stem Cell Therapy Market Size Sales Growth Clinical T …
Global Cell Therapy Market Size Sales Opportunity To Surpass USD 40 Billion By 2027 Says Kuick Research Report Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027 "Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market: > USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Cell Therapy Price & Product Insight By Region/Country • Clinical
Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Bi …
"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026 • USA Dominates Global Small Molecule Cancer Drug Market: >50% Share • Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs • Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs • Small Molecule Drug Insight by Cancer • Clinical Trials Insight
GCC Clinical Trial Market Outlook Insight 2025
"GCC Clinical Trial Market Outlook 2025" Report Highlights: • GCC Clinical Trial Market Opportunity: >US$ 500 Million • GCC Disease Prevalence & Statistics • Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials • Clinical Trials for Cancer in GCC: > 120 Trials • Guidelines For Conducting Clinical Trials by Country • Ongoing Clinical Trials Insight by Country Download Report: https://www.kuickresearch.com/report-report-report-report-report-report-report-report-gcc-clinical-trial-market-size-number--data-regulation-registration Table of Contents 1. GCC Clinical Market Regional Insights 2. GCC Clinical Trial Market Dynamics 2.1 Driving Forces for GCC Clinical Trial

All 5 Releases


More Releases for Radiopharmaceutical

A Comprehensive Study exploring Radiopharmaceutical Market | Bayer, Triad Isotop …
A latest survey on Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Radiopharmaceutical Market is conducted covering various organizations of the industry from different geographies to come up with 100+ page report. The study is a perfect mix of qualitative and quantitative information highlighting key market developments, challenges that industry and competition is facing along with gap analysis and new opportunity available and may trend in
Radiopharmaceutical Devices Global Industry Report - History, Present and Future …
The global market size of Radiopharmaceutical Devices is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023. There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment. For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented
Global Radiopharmaceutical Market Analysis and Forecast Predictions
The market for Radiopharmaceutical Market growing with the expansion of this Industry Sector Worldwide. Market Research Report Search Engine (MRRSE) has added a new report titled “Radiopharmaceutical Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2024”which offer details about the current trends as well as scope for the near future. This research study also covers information about the production and market share based on different
Radiopharmaceutical Market | Analysis & Key Trends 2024
Radiopharmaceutical Market: Snapshot The global market for radiopharmaceuticals is poised for steady growth in the coming years, driven primarily by the rising use of radioisotopes for the treatment of various diseases, such as cancer, bone palliation, neurological disorders, and cardiovascular diseases. Around 35 million patients undergo treatment procedures for these diseases each year and this will continue to boost the demand for radiopharmaceuticals. According to the Nuclear Energy Institute, radioisotopes are essential
Radiopharmaceutical Market: Market and Growth Analysis 2024
Radiopharmaceutical Market: Snapshot The global market for radiopharmaceuticals is poised for steady growth in the coming years, driven primarily by the rising use of radioisotopes for the treatment of various diseases, such as cancer, bone palliation, neurological disorders, and cardiovascular diseases. Around 35 million patients undergo treatment procedures for these diseases each year and this will continue to boost the demand for radiopharmaceuticals. According to the Nuclear Energy Institute, radioisotopes are essential
Radiopharmaceutical Market Development Status and Outlook 2024
Radiopharmaceutical Market: Snapshot The global market for radiopharmaceuticals is poised for steady growth in the coming years, driven primarily by the rising use of radioisotopes for the treatment of various diseases, such as cancer, bone palliation, neurological disorders, and cardiovascular diseases. Around 35 million patients undergo treatment procedures for these diseases each year and this will continue to boost the demand for radiopharmaceuticals. Read Report Overview for Radiopharmaceutical Market: http://www.transparencymarketresearch.com/radiopharmaceuticals-market.html According to the